Definium Therapeutics, Inc. $DFTX Shares Newly Purchased by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC bought a new stake in Definium Therapeutics, Inc. (NASDAQ:DFTX) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 69,550 shares of the company’s stock, valued at approximately $2,647,000.

Several other large investors have also recently bought and sold shares of DFTX. Pictet Asset Management Holding SA increased its position in Definium Therapeutics by 32.7% in the 3rd quarter. Pictet Asset Management Holding SA now owns 18,674 shares of the company’s stock valued at $711,000 after acquiring an additional 4,597 shares during the period. AlphaCentric Advisors LLC acquired a new stake in shares of Definium Therapeutics in the third quarter valued at about $366,000. Alps Advisors Inc. increased its stake in shares of Definium Therapeutics by 61.3% in the third quarter. Alps Advisors Inc. now owns 178,006 shares of the company’s stock valued at $6,775,000 after buying an additional 67,618 shares during the period. Commonwealth Equity Services LLC boosted its stake in shares of Definium Therapeutics by 4.0% in the 3rd quarter. Commonwealth Equity Services LLC now owns 9,832 shares of the company’s stock valued at $374,000 after purchasing an additional 382 shares during the last quarter. Finally, TFB Advisors LLC grew its holdings in Definium Therapeutics by 2.5% during the 3rd quarter. TFB Advisors LLC now owns 22,064 shares of the company’s stock worth $840,000 after acquiring an additional 541 shares during the period. 27.91% of the stock is currently owned by institutional investors.

Definium Therapeutics Trading Down 0.5%

NASDAQ DFTX opened at $34.47 on Thursday. Definium Therapeutics, Inc. has a twelve month low of $10.46 and a twelve month high of $49.70. The firm has a market capitalization of $4.63 billion, a PE ratio of -11.08 and a beta of 2.23. The company has a quick ratio of 6.95, a current ratio of 15.53 and a debt-to-equity ratio of 0.04. The stock’s 50 day moving average is $36.31 and its 200 day moving average is $30.23.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.09. Research analysts forecast that Definium Therapeutics, Inc. will post -3.08 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DFTX has been the topic of several research reports. Canaccord Genuity Group set a $78.00 price objective on shares of Definium Therapeutics and gave the company a “buy” rating in a report on Tuesday, September 15th. Piper Sandler restated an “overweight” rating and set a $75.00 target price (up from $73.00) on shares of Definium Therapeutics in a research report on Friday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a report on Thursday, October 15th. Needham & Company LLC restated a “buy” rating and issued a $66.00 target price on shares of Definium Therapeutics in a research report on Monday, September 14th. Finally, Robert W. Baird lifted their price target on Definium Therapeutics from $75.00 to $79.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $66.24.

Recent Definium Therapeutics Headlines

Investors following DFTX have been watching these headlines:

• Positive Sentiment: Definium reported a third-quarter loss of $0.46 per share, narrower than analysts’ expected loss of $0.55. Commentary also points to clinical momentum following DT120 Phase 3 data, which may support investor interest in the pipeline. Third-quarter results DT120 analysis
• Neutral Sentiment: The company announced a planned webcast about its third-quarter results and presentations of DT120 Phase 3 data at the NEI Congress. These events may provide more information, but the announcements themselves do not report new trial findings. Planned webcast NEI Congress presentations
• Negative Sentiment: One analysis argues that the stock’s valuation looks inflated despite the potential for future approval. RBC also characterized the investment as carrying speculative risk, underscoring uncertainty around clinical development and commercialization. Valuation analysis

Insider Buying and Selling at Definium Therapeutics

In other news, insider Mark Sullivan sold 14,051 shares of Definium Therapeutics stock in a transaction that occurred on Friday, September 25th. The shares were sold at an average price of $36.57, for a total transaction of $513,845.07. Following the completion of the transaction, the insider directly owned 494,228 shares in the company, valued at approximately $18,073,917.96. This trade represents a 2.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Brandi Roberts sold 3,377 shares of Definium Therapeutics stock in a transaction that occurred on Friday, September 25th. The shares were sold at an average price of $36.57, for a total transaction of $123,496.89. Following the transaction, the chief financial officer owned 394,528 shares of the company’s stock, valued at $14,427,888.96. The trade was a 0.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 71,098 shares of company stock worth $2,626,115. Insiders own 2.40% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026.